{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-148107","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.431699+00:00","generated_at":"2026-06-01T08:29:19.855329+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine CEO Kevin Gorman to retire Oct 11; Kyle Gano appointed successor","bullets":["Kevin C. Gorman, Ph.D. to retire as President and CEO effective October 11, 2024; will remain on the board.","Kyle Gano, Ph.D., current Chief Business Development and Strategy Officer, becomes President and CEO on same date.","Gano appointed to the board as a Class II director effective October 11, 2024.","Board size increased from 10 to 11 via bylaw amendment to accommodate Gano's appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-148107","json":"https://secwatch.observer/filing/0001193125-24-148107.json","markdown":"https://secwatch.observer/filing/0001193125-24-148107.md","text":"https://secwatch.observer/filing/0001193125-24-148107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/d836271d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:29:19.855329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10f4c05fc9","claim":"Kevin C. Gorman retired as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"Kevin C. Gorman, Ph.D. will retire as Neurocrine’s President and Chief Executive Officer effective as of October 11, 2024 (the “Transition Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"63c7ce5383","claim":"Kyle Gano was appointed as Class II Director at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"effective as of the Transition Date, Dr. Gano has been appointed to the Board as a Class II director to serve until Neurocrine’s 2025 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"c3ecb2d928","claim":"Kyle Gano was appointed as President and Chief Executive Officer at NEUROCRINE BIOSCIENCES INC.","evidence_excerpt":"appointment of Kyle Gano, Ph.D., age 51, to serve as Neurocrine’s President and Chief Executive Officer, effective as of the Transition Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312524148107/0001193125-24-148107-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}